Labeler
Amgen, Inc NDC Codes
Amgen, Inc lists 87 finished drug products in the FDA NDC Directory under NDC labeler code 55513.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Aranesp, Amjevita, Otezla, Epogen, Aimovig, Neupogen, Neulasta, Evenity, Lumakras, Nplate, Corlanor, Parsabiv, Sensipar, Pavblu, Imdelltra (Amg757)
- Active ingredients
- Darbepoetin alfa, Adalimumab, Epoetin, Erenumab, Filgrastim, Romosozumab, Apremilast, Sotorasib, Romiplostim, Ivabradine hydrochloride, Etelcalcetide hydrochloride, Cinacalcet hydrochloride
- NDC labeler codes
- 55513
- Strengths
- Romosozumab 105 mg/1.17mL; Aflibercept 2 mg/.05mL; Adalimumab 40 mg/.4mL; Adalimumab 80 mg/.8mL; Adalimumab 40 mg/.8mL; Tezepelumab 210 mg/1.9mL; Erenumab 140 mg/mL; Erenumab 70 mg/mL; Epoetin 10000 [iU]/mL; Pegfilgrastim 4 mg/.4mL; Apremilast 75 mg/1; Eculizumab 300 mg/30mL; Sotorasib 240 mg/1; Apremilast 20 mg/1; Adalimumab 20 mg/.2mL; Adalimumab 10 mg/.2mL; Sotorasib 320 mg/1; Adalimumab 20 mg/.4mL; Sotorasib 120 mg/1; Rituximab 500 mg/50mL
- Dosage forms
- Injection, Solution, Solution, Injection, Kit, Tablet, Coated, Injection, Powder, Lyophilized, For solution, Tablet, Film coated, Injection, Suspension, Injection, Solution, Concentrate
- Routes
- Subcutaneous, Intravenous, Oral, Intravitreal, Intralesional
- Drug classes (FDA established)
- Erythropoiesis-stimulating Agent, Tumor Necrosis Factor Blocker, Leukocyte Growth Factor, Calcium-sensing Receptor Agonist, Vascular Endothelial Growth Factor Inhibitor, Phosphodiesterase 4 Inhibitor, Thrombopoietin Receptor Agonist, Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker, Thymic Stromal Lymphopoietin Blocker, CD20-directed Cytolytic Antibody, HER2/neu Receptor Antagonist, RANK Ligand Inhibitor, Epidermal Growth Factor Receptor Antagonist, Complement Inhibitor
- HCPCS / J-code
- J2506 — Injection, pegfilgrastim, excludes biosimilar, 0.5 mg, J0178 — Injection, aflibercept, 1 mg, J0135 — Injection, adalimumab, 20 mg, J9312 — Injection, rituximab, 10 mg, J1745 — Injection, infliximab, excludes biosimilar, 10 mg, J9355 — Injection, trastuzumab, excludes biosimilar, 10 mg, J9035 — Injection, bevacizumab, 10 mg, J0897 — Injection, denosumab, 1 mg
- Package NDCs
- 135
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Neulastapegfilgrastim | Pegfilgrastim 4 mg/.4mL | SolutionSubcutaneous | 55513-099 | 55513-0099-01 | J2506 |
| Evenityromosozumab-aqqg | Romosozumab 105 mg/1.17mL | Injection, SolutionSubcutaneous | 55513-509 | 55513-0509-02 | — |
| Otezlaapremilast | — | Kit | 55513-516 | 55513-0516-41 | — |
| Otezlaapremilast | Apremilast 75 mg/1 | Tablet, Film coatedOral | 55513-519 | 55513-0519-30 | — |
| Bkemveculizumab-aeeb | Eculizumab 300 mg/30mL | Injection, Solution, ConcentrateIntravenous | 55513-180 | 55513-0180-01 | — |
| Pavbluaflibercept-ayyh | Aflibercept 2 mg/.05mL | Injection, SolutionIntravitreal | 55513-056 | 55513-0056-0155513-0056-96 | J0178 |
| Pavbluaflibercept-ayyh | Aflibercept 2 mg/.05mL | Injection, SolutionIntravitreal | 55513-065 | 55513-0065-0155513-0065-96 | J0178 |
| Evenityromosozumab-aqqg | Romosozumab 105 mg/1.17mL | Injection, SolutionSubcutaneous | 55513-998 | 55513-0998-02 | — |
| Lumakrassotorasib | Sotorasib 240 mg/1 | Tablet, CoatedOral | 55513-512 | 55513-0512-60 | — |
| Imdelltra (Amg757)tarlatamab-dlle | — | Kit | 55513-059 | 55513-0059-01 | — |
| Imdelltra (Amg757)tarlatamab-dlle | — | Kit | 55513-077 | 55513-0077-01 | — |
| Otezlaapremilast | Apremilast 20 mg/1 | Tablet, Film coatedOral | 55513-497 | 55513-0497-60 | — |
| Otezlaapremilast | — | Kit | 55513-508 | 55513-0508-55 | — |
| Otezlaapremilast | — | Kit | 55513-996 | 55513-0996-95 | — |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | 55513-399 | 55513-0399-01 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | 55513-479 | 55513-0479-0155513-0479-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | 55513-480 | 55513-0480-0155513-0480-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | 55513-481 | 55513-0481-0155513-0481-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | 55513-482 | 55513-0482-0155513-0482-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 10 mg/.2mL | InjectionSubcutaneous | 55513-413 | 55513-0413-01 | J0135 |
| Lumakrassotorasib | Sotorasib 320 mg/1 | Tablet, CoatedOral | 55513-504 | 55513-0504-50 | — |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | 55513-400 | 55513-0400-0155513-0400-0255513-0400-91 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | 55513-410 | 55513-0410-0155513-0410-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.4mL | InjectionSubcutaneous | 55513-411 | 55513-0411-01 | J0135 |
| Tezspiretezepelumab-ekko | Tezepelumab 210 mg/1.9mL | Injection, SolutionSubcutaneous | 55513-112 | 55513-0112-0155513-0112-96 | — |
| Tezspiretezepelumab-ekko | Tezepelumab 210 mg/1.9mL | Injection, SolutionSubcutaneous | 55513-123 | 55513-0123-0155513-0123-96 | — |
| Lumakrassotorasib | Sotorasib 120 mg/1 | Tablet, CoatedOral | 55513-488 | 55513-0488-0255513-0488-2455513-0488-96 | — |
| Riabnirituximab-arrx | Rituximab 500 mg/50mL | Injection, SolutionIntravenous | 55513-326 | 55513-0326-0155513-0326-21 | J9312 |
| Riabnirituximab-arrx | Rituximab 100 mg/10mL | Injection, SolutionIntravenous | 55513-224 | 55513-0224-0155513-0224-21 | J9312 |
| Otezlaapremilast | — | Kit | 55513-369 | 55513-0369-55 | — |
| Otezlaapremilast | — | Kit | 55513-485 | 55513-0485-96 | — |
| Otezlaapremilast | Apremilast 30 mg/1 | Tablet, Film coatedOral | 55513-137 | 55513-0137-6055513-0137-95 | — |
| Avsolainfliximab-axxq | Infliximab 100 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | 55513-670 | 55513-0670-0155513-0670-21 | J1745 |
| Kanjintitrastuzumab-anns | Trastuzumab 150 mg/7.15mL | Injection, Powder, Lyophilized, For solutionIntravenous | 55513-141 | 55513-0141-0155513-0141-21 | J9355 |
| Nplateromiplostim | Romiplostim 125 ug/.25mL | Injection, Powder, Lyophilized, For solutionSubcutaneous | 55513-223 | 55513-0223-0155513-0223-21 | — |
| Kanjintitrastuzumab-anns | Trastuzumab 420 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | 55513-132 | 55513-0132-0155513-0132-21 | J9355 |
| Corlanorivabradine | Ivabradine hydrochloride 5 mg/5mL | SolutionOral | 55513-813 | 55513-0813-28 | — |
| Evenityromosozumab-aqqg | Romosozumab 105 mg/1.17mL | Injection, SolutionSubcutaneous | 55513-880 | 55513-0880-02 | — |
| Aimovigerenumab-aooe | Erenumab 140 mg/mL | Injection, SolutionSubcutaneous | 55513-842 | 55513-0842-01 | — |
| Aimovigerenumab-aooe | Erenumab 140 mg/mL | Injection, SolutionSubcutaneous | 55513-843 | 55513-0843-0055513-0843-01 | — |
| Mvasibevacizumab-awwb | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | 55513-206 | 55513-0206-0155513-0206-21 | J9035 |
| Mvasibevacizumab-awwb | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | 55513-207 | 55513-0207-0155513-0207-21 | J9035 |
| Aimovigerenumab-aooe | Erenumab 70 mg/mL | InjectionSubcutaneous | 55513-840 | 55513-0840-01 | — |
| Aimovigerenumab-aooe | Erenumab 70 mg/mL | InjectionSubcutaneous | 55513-841 | 55513-0841-0055513-0841-01 | — |
| Parsabivetelcalcetide | Etelcalcetide hydrochloride 2.5 mg/.5mL | Injection, SolutionIntravenous | 55513-740 | 55513-0740-1055513-0740-20 | — |
| Parsabivetelcalcetide | Etelcalcetide hydrochloride 5 mg/mL | Injection, SolutionIntravenous | 55513-741 | 55513-0741-1055513-0741-20 | — |
| Parsabivetelcalcetide | Etelcalcetide hydrochloride 10 mg/2mL | Injection, SolutionIntravenous | 55513-742 | 55513-0742-1055513-0742-20 | — |
| Imlygictalimogene laherparepvec | Talimogene laherparepvec 1000000 [PFU]/mL | Injection, SuspensionIntralesional | 55513-078 | 55513-0078-01 | — |
| Imlygictalimogene laherparepvec | Talimogene laherparepvec 100000000 [PFU]/mL | Injection, SuspensionIntralesional | 55513-079 | 55513-0079-01 | — |
| Corlanorivabradine | Ivabradine hydrochloride 5 mg/1 | Tablet, Film coatedOral | 55513-800 | 55513-0800-6055513-0800-99 | — |
Amgen, Inc: common questions
- What is Amgen, Inc's NDC labeler code?
- 55513. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Amgen, Inc?
- Med-Code's HCPCS directory matches J2506, J0178, J0135, J9312, J1745, J9355, J9035, J0897 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.